NCT03873116View on ClinicalTrials.gov

Study to Evaluate the Efficacy and Safety of BCX7353 as an Oral Treatment for the Prevention of HAE Attacks in Japan

PHASE3CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

December 27, 2018

Primary Completion Date

July 8, 2021

Study Completion Date

July 8, 2021

Conditions
Hereditary Angioedema, HAE
Interventions
DRUG

BCX7353 capsules

BCX7353 capsules administered orally once daily

DRUG

BCX7353 capsules

BCX7353 capsules administered orally once daily

DRUG

Placebo oral capsule

Matching placebo capsules administered orally once daily

Trial Locations (10)

Unknown

Study Site, Chiba

Study Site, Gunma

Study Site, Hokkaido

Study Site, Nagoya

Study Site, Osaka

Study Center, Saga

Study Site, Saitama

Study Site, Shimane

Study Site, Shizuoka

Study Site, Tokyo

Sponsors
All Listed Sponsors
lead

BioCryst Pharmaceuticals

INDUSTRY

NCT03873116 - Study to Evaluate the Efficacy and Safety of BCX7353 as an Oral Treatment for the Prevention of HAE Attacks in Japan | Biotech Hunter | Biotech Hunter